Ernest Pedapati

Professor, UC Department of Psychiatry and Behavioral Neuroscience Cincinnati Children’s Hospital

I specialize in the treatment of neuropsychiatric diseases associated with ASD, genetic, and other neurodevelopmental disorders, including interdisciplinary treatment planning and advanced medication management. Prior to my faculty appointment, I received clinical and research training under Craig Erickson, MD, and pediatric transcranial magnetic stimulation under Donald Gilbert, MD, MS.
In 2013, I successfully designed and obtained IRB approval and competitive funding for a TMS project through the American Academy of Child & Adolescent Psychiatry Pilot Research Award. I am currently completing the study, “Cortical Plasticity in Adolescent Depression,” which aims to use TMS to determine whether abnormal neuroplasticity can be quantified in adolescent depression.
During my final year of residency, I applied for and secured a highly competitive institutional mentor career development award (Procter Scholar), which allowed me to dedicate 90% of my time to independent research activities. This included obtaining preliminary data on TMS measures of cortical plasticity in ASD and developing an implicit false belief task of social cognition for future TMS modulation. Additionally, I continue to be an active subinvestigator, extensively contributing to an NIH R01 project examining TMS measures of motor physiology in ADHD. I pioneered the use of SICI as a biomarker in ADHD and the measurement of cortical plasticity in healthy youth.

Seminars

Tuesday 15th September 2026
Decision Grade EEG Biomarkers to De Risk Early Neuropsychiatric Drug Development: Case Study in Fragile X & Schizophrenia
1:00 pm
  • Using EEG as a sensitive, translational readout of drug-target engagement in small first in human studies across Fragile X, schizophrenia, and other brain disorders
  • Demonstrating rapid rescue and normalisation of disease relevant EEG signals following acute dosing and linking these changes to clinically meaningful cognitive outcomes
  • Pairing EEG biomarkers with regulatory acceptable endpoints, including NIH Toolbox measures, to strengthen confidence in early proof of concept
  • Applying EEG based responder identification to de risk progression into larger Phase 2 and 3 trials across heterogeneous neuropsychiatric populations